Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
Commentary|Podcasts|September 7, 2023
Public Health Matters - Current Issues in Oncology Space
Christina Madison, PharmD, FCCP, AAHIVP, speaks with Ryan Haumschild, PharmD, MS, MBA, to discuss current issues in oncology, including drug shortages and patient access.
Advertisement
On this episode of Public Health Matters, Christina Madison, PharmD, FCCP, AAHIVP, spoke with Ryan Haumschild, PharmD, MS, MBA, to discuss current issues in oncology, including drug shortages and patient access.
Ryan Haumschild, PharmD, MS, MBA, is the director of pharmacy services at Emory Healthcare and Winship Cancer Institute in Atlanta, Georgia.
Advertisement
Related to this article
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
4
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
5